You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Citation Tools

Article menu
Immunotherapy biomarkers
Original research
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
West HJ, McCleland M, Cappuzzo F, et al
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Journal for ImmunoTherapy of Cancer 2022;10:e003027. doi: 10.1136/jitc-2021-003027